<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03659136</url>
  </required_header>
  <id_info>
    <org_study_id>1280-0022</org_study_id>
    <secondary_id>2017-003131-11</secondary_id>
    <nct_id>NCT03659136</nct_id>
  </id_info>
  <brief_title>The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread</brief_title>
  <official_title>XENERA™1: A Multi-centre, Double-blind, Placebo-controlled, Randomised Phase II Trial to Compare Efficacy of Xentuzumab in Combination With Everolimus and Exemestane Versus Everolimus and Exemestane in Women With HR+ / HER2- Metastatic Breast Cancer and Non-visceral Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the trial is to assess the anti-tumor activity of xentuzumab in
      combination with everolimus and exemestane over everolimus and exemestane in patients with
      HR+/ HER2- advanced or metastatic breast cancer and non-visceral disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 28, 2018</start_date>
  <completion_date type="Anticipated">November 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS) as assessed by central review</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Defined as time from randomisation until disease progression according to Response Evaluation Criteria In Solid Tumors (RECIST, version 1.1) or death from any cause, whichever occurs earlier</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) defined as the time from randomisation until death from any cause</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Defined as the time from randomisation until death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control (DC)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Defined as a best overall response of complete response (CR), partial response (PR), stable disease (SD) or Non-CR/Non-Progressive Disease (Non- CR/Non-PD). SD and Non-CR/Non PD must have a minimum duration of 24 weeks from randomisation. Best overall response is defined according to RECIST version 1.1 and will consider all tumour assessments from randomisation until the earliest of disease progression, death or last evaluable tumour assessment before start of subsequent anticancer therapy, loss to follow-up or withdrawal of consent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of DC is defined as the time from randomisation until the earliest of disease progression or death, among patients with DC</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Defined as the time from randomisation until the earliest of disease progression or death, among patients with DC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response (OR) Defined as a best overall response of complete response (CR) or partial response (PR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Defined as a best overall response of CR or PR. Best overall response is defined according to RECIST version 1.1 and will consider all tumour assessments from randomisation until the earliest of disease progression, death or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up or withdrawal of consent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to pain progression or intensification of pain palliation</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Defined as the time from randomisation until the earliest of a clinically significant increase in pain (≥2-point increase from baseline in the Brief Pain Inventory- Short Form [BPI-SF] Item 3) without a decrease in analgesics use, or intensification in pain palliation (≥2-point increase in the 8-point Analgesic Quantification Algorithm [AQA]), or death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Xentuzumab/everolimus/exemestane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo/everolimus/exemestane</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Xentuzumab</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Xentuzumab/everolimus/exemestane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Placebo/everolimus/exemestane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Placebo/everolimus/exemestane</arm_group_label>
    <arm_group_label>Xentuzumab/everolimus/exemestane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Placebo/everolimus/exemestane</arm_group_label>
    <arm_group_label>Xentuzumab/everolimus/exemestane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented histologically confirmed breast cancer with ERand/ or PgR-positive and
             HER2-negative status

          -  Locally advanced or metastatic breast cancer not deemed amenable to curative surgery
             or curative radiation therapy

          -  Archival tumour sample available at the time of informed consent and provided to the
             central laboratory around the time of randomisation. Patients must provide a
             formalin-fixed paraffin embedded (FFPE) tissue biopsy sample preferably taken at the
             time of presentation with recurrent or metastatic disease (provision of a biopsy
             sample taken from the bone is not acceptable).

          -  Patients must satisfy the following criteria for prior therapy:

               -  Disease progression during treatment or within 12 months of completion of
                  endocrine adjuvant therapy or

               -  Disease progression while on or within 1 month after the end of prior endocrine
                  therapy for advanced/metastatic breast cancer (Note: the endocrine therapy does
                  not have to be the treatment immediately prior to trial entry).

          -  Patients must have

               -  At least one measurable non-visceral lesion according to RECIST version 1.1 in
                  either lymph nodes, soft tissue, skin and/or

               -  At least one measurable non-visceral lesion according to RECIST version 1.1 as
                  lytic or mixed (lytic + blastic) in bone and/or

               -  At least one non-measurable (lytic, mixed lytic + blastic, or blastic) bone
                  lesion according to RECIST version 1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.

          -  Adequate organ function

        Exclusion Criteria:

          -  Previous treatment with agents targeting the IGF pathway, AKT, or mTOR pathways

          -  Prior treatment with exemestane (except adjuvant exemestane stopped &gt;12 months prior
             to start of study treatment as long as the patient did not recur during or within 12
             months after the end of adjuvant exemestane)

          -  Evidence of visceral metastasis/es (i.e. liver, lung, peritoneal, pleural metastases,
             malignant pleural effusions, malignant peritoneal effusions) at screening. NOTE:
             Patients with a past history of visceral metastases are eligible if visceral
             metastases have completely resolved at least 3 months

          -  History or evidence of metastatic disease to the brain

          -  Leptomeningeal carcinomatosis

          -  More than 1 prior line of chemotherapy for HR+ HER2- metastatic breast cancer

          -  Radiotherapy within 4 weeks prior to the start of study treatment

          -  Use of concomitant systemic sex hormone therapy

          -  History or presence of cardiovascular abnormalities

          -  Known pre-existing interstitial lung disease

          -  Further exclusion criteria apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ironwood Cancer and Research Centers</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhail Shtivelband</last_name>
      <phone>+001 (480) 821-2838</phone>
      <email>shtivelband@ironwoodcrc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America at Western Regional Medical Center</name>
      <address>
        <city>Goodyear</city>
        <state>Arizona</state>
        <zip>85338</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Lynch</last_name>
      <phone>+001 (623) 207 3000</phone>
      <email>cynthia.lynch@ctca-hope.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Schaefer</last_name>
      <phone>+001 (479) 936-9900</phone>
      <email>eschaefer@hogonc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beverly Hills Cancer Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Oncology Physicians Network of California, PC</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Lam</last_name>
      <phone>+001 (818) 507-4732</phone>
      <email>dr.anthony.lam@opnhc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hope Rugo</last_name>
      <phone>+001 (415) 353-7618</phone>
      <email>Hope.Rugo@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lowell Hart</last_name>
      <phone>+001 (239) 940-6890</phone>
      <email>llhart@flcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Cancer and Blood Center</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Petros Nikolinakos</last_name>
      <phone>+001 (706) 353-2990</phone>
      <email>CTPN@UNIVERSITYCANCER.COM</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southeastern Regional Medical Center</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien Hansra</last_name>
      <phone>+001 (770) 400-6000</phone>
      <email>damien.hansra@ctca-hope.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advocate Medical Group Oncology</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America</name>
      <address>
        <city>Zion</city>
        <state>Illinois</state>
        <zip>60099</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Beckwith</last_name>
      <phone>+001 (612) 625-4918</phone>
      <email>einho003@umn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HCA Midwest Division</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Graff</last_name>
      <phone>+001 (816) 276 4700</phone>
      <email>Stephanie.graff@hcahealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of Rockland</name>
      <address>
        <city>Nyack</city>
        <state>New York</state>
        <zip>10960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Ho Lee</last_name>
      <phone>+001 (845) 480-7440</phone>
      <email>lees@MontefioreNyack.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Specialists of Charlotte, PA</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Favaro</last_name>
      <phone>+001 (704) 342 1900</phone>
      <email>favarojp77@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southwestern Regional Medical Center</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74133</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sagun Shrestha</last_name>
      <phone>+001 (918) 286-5000</phone>
      <email>Sagun.shrestha@ctca-hope.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America at Eastern Regional Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard Burris</last_name>
      <phone>+001 (615) 329-7274</phone>
      <email>hburris@tnonc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer and Blood Disorders</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robyn Young</last_name>
      <phone>+001 (817) 759-7000</phone>
      <email>ryoung@txcc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Utah Cancer Specialists Cancer Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S. Kendall</last_name>
      <phone>+001 (801) 281 6864</phone>
      <email>studies@utahcancer.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties, PLLC</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sibel Blau</last_name>
      <phone>+001 (253) 428-8700</phone>
      <email>blau_research@nwmsonline.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Tweed Hospital</name>
      <address>
        <city>Tweed Heads</city>
        <state>New South Wales</state>
        <zip>2485</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ratnesh Srivastav</last_name>
      <phone>61 7 55067296</phone>
      <email>ratnesh.srivastav@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Box Hill Hospital</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Peninsula Haematology &amp; Oncology</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Brussels - UNIV UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christel Fontaine</last_name>
      <phone>+32 (0)2 477 64 15</phone>
      <email>christel.fontaine@uzbrussel.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brussels - UNIV Saint-Luc</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François Duhoux</last_name>
      <phone>+32 (0)71</phone>
      <email>francois.duhoux@uclouvain.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kortrijk - HOSP AZ Groeninge Kennedylaan</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marleen Borms</last_name>
      <phone>+32 (0)56 63 39 00</phone>
      <email>marleen.borms@azgroeninge.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Neven</last_name>
      <phone>+32 (0)16 34 46 34</phone>
      <email>patrick.neven@uzleuven.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre (MUHC)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec-Universite Laval Research Centre</name>
      <address>
        <city>Quebec</city>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Lemieux</last_name>
      <phone>418-649-0252</phone>
      <email>julie.lemieux@crchudequebec.ulaval.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>INS Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Grenier</last_name>
      <phone>+33 (0)4 90 27 63 97</phone>
      <email>j.grenier@isc84.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CLI Bordeaux Nord Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadine Dohollou</last_name>
      <phone>+33 (0)5 56 43 73 54</phone>
      <email>n.dohollou@bordeauxnord.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Victor Hugo</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugues Bourgeois</last_name>
      <phone>+33 (0)2 43 29 79 88</phone>
      <email>essaisbourgeois@i-l-c.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>INS Paoli-Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Goncalves</last_name>
      <phone>+33 (0)4 91 22 35 37</phone>
      <email>goncalvesa@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>INS Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Ricci</last_name>
      <phone>+33 (0)1 44 32 46 06</phone>
      <email>francesco.ricci@curie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Européen G. Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Medioni</last_name>
      <phone>+33 (0)1 56 09 27 81</phone>
      <email>jacques.medioni@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benoît You</last_name>
      <phone>+33 (0)4 78 86 43 18</phone>
      <email>benoit.you@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>INS Universitaire du Cancer</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Dalenc</last_name>
      <phone>+33 (0)5 31 15 51 22</phone>
      <email>dalenc.florence@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Fasching</last_name>
      <phone>09131 853-3451</phone>
      <email>Peter.fasching.studien@uk-erlangen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Fuxius</last_name>
      <phone>+49 (6221) 714990</phone>
      <email>stefanfuxius@gmx.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vincentius-Diakonissen-Kliniken gAG</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76135</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Tomé</last_name>
      <phone>+49 (721) 81089003</phone>
      <email>oliver.tome@vincentius-ka.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Elisabeth-Krankenhaus</name>
      <address>
        <city>Köln</city>
        <zip>50935</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Schumacher</last_name>
      <phone>+49 (221) 46772301</phone>
      <email>claudia.schumacher@hohenlind.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Hartkopf</last_name>
      <phone>+49 (7071) 2982236</phone>
      <email>Andreas.Hartkopf@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Heraklion</name>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Larisa, Oncology Clinic</name>
      <address>
        <city>Larisa</city>
        <zip>41334</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Athanasios Kotsakis</last_name>
      <phone>00302810392783</phone>
      <email>thankotsakis@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital, Oncology Clinic</name>
      <address>
        <city>Neo Faliro, Athens</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helena Linardou</last_name>
      <phone>+302104809852</phone>
      <email>elinardou@otenet.gr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Euromedica Kyanous Stavros General Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54645</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantinos Papazisis</last_name>
      <phone>+302310895362</phone>
      <email>konstantinos.papazisis@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Fondazione Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelino De Laurentiis</last_name>
      <phone>+39 (081) 33775831</phone>
      <email>delauren@breastunit.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Iov, Irccs</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Sant'Andrea-Università di Roma La Sapienza</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Marchetti</last_name>
      <phone>+39 (06) 33775831</phone>
      <email>marchetti.paaolo@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Braga - Centro Clínico Académico (2CA)</name>
      <address>
        <city>Braga</city>
        <zip>4710-243</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catarina Portela</last_name>
      <phone>+351 253209000</phone>
      <email>portela.catarina@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundação Champalimaud,</name>
      <address>
        <city>Lisboa</city>
        <zip>1400-038</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fátima Cardoso</last_name>
      <phone>+351 210 480 200</phone>
      <email>fatimacardoso@fundacaochampalimaud.pt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Beatriz Ângelo</name>
      <address>
        <city>Loures</city>
        <zip>2674-514</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Coelho</last_name>
      <phone>+351 219 847 200</phone>
      <email>jlpassoscoelho@hbeatrizangelo.pt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>USLM, EPE - Hospital Pedro Hispano</name>
      <address>
        <city>Matosinhos</city>
        <zip>4464-513</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matilde Salgado</last_name>
      <phone>+351 22 9391276</phone>
      <email>matilde.salgado@ulsm.min-saude.pt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universitário do Porto, EPE - Hospital de Santo António</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noémia Afonso</last_name>
      <phone>+351 22 207 7500</phone>
      <email>noemia.afonso@netcabo.pt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Vila Nova de Gaia</name>
      <address>
        <city>Vila Nova de Gaia</city>
        <zip>4434-502</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>António Pinto</last_name>
      <phone>+351227865100</phone>
      <email>moreira.pinto@chvng.min-saude.pt</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Teresa Herrera</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Antolín Novoa</last_name>
      <phone>+34981178000 ext.292022</phone>
      <email>Silvia.Antolin.Novoa@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Gómez Pardo</last_name>
      <phone>+34932746085</phone>
      <email>pgomez@vhio.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Jesús Vidal Losada</last_name>
      <phone>+34932275402</phone>
      <email>mjvidal@clinic.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Serafín Morales</last_name>
      <phone>+34973705351</phone>
      <email>serafinmorales01@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara López-Tarruella</last_name>
      <phone>+34914269070</phone>
      <email>slopeztarruella@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noelia Martínez Jañez</last_name>
      <phone>+34913368263</phone>
      <email>mjnoelia@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Angel García Sáenz</last_name>
      <phone>+34913303000 ext.7768</phone>
      <email>jagsaenz@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Díaz Redondo</last_name>
      <phone>+34951032508</phone>
      <email>tdredondo@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanesa Varela</last_name>
      <phone>+34981950000</phone>
      <email>vanesa.varela.pose@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ángel Luis Guerrero Zotano</last_name>
      <phone>+34961104606</phone>
      <email>angel.guerrero.zotano@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Quirón de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés Poveda</last_name>
      <phone>+34963690600</phone>
      <email>apoveda@initiaoncologia.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandro Pérez Fidalgo</last_name>
      <phone>+34961973500</phone>
      <email>japfidalgo@msn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 3, 2018</study_first_submitted>
  <study_first_submitted_qc>September 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2018</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:
Studies in products where Boehringer Ingelheim is not the license holder;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;
Studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).
Requestors can use the following link http:// trials.boehringer-ingelheim.com/ to:
find information in order to request access to clinical study data, for listed studies.
request access to clinical study documents that meet criteria, and upon a signed 'Document Sharing Agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

